Pharmaceutics 2021, 13, 850
14 of 16
27. Morales-Camilo, N.; Salas, C.O.; Sanhueza, C.; Espinosa-Bustos, C.; Sepúlveda-Boza, S.; Reyes-Parada, M.; Gonzalez-Nilo, F.;
Caroli-Rezende, M.; Fierro, A. Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective
MAO-B inhibitors. Chem. Biol. Drug Des. 2015, 85, 685–695. [CrossRef]
28. Choi, J.W.; Jang, B.K.; Cho, N.C.; Park, J.H.; Yeon, S.K.; Ju, E.J.; Lee, Y.S.; Han, G.; Pae, A.N.; Kim, D.J.; et al. Synthesis of a series of
unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg. Med. Chem. 2015, 23, 6486–6496.
29. Hammuda, A.; Shalaby, R.; Rovida, S.; Edmondson, D.E.; Binda, C.; Khalil, A. Design and synthesis of novel chalcones as potent
selective monoamine oxidase-B inhibitors. Eur. J. Med. Chem. 2016, 114, 162–169. [CrossRef]
30. Mathew, B.; Uçar, G.; Mathew, G.E.; Mathew, S.; Purapurath, K.P.; Moolayil, F.; Mohan, S.; Gupta, S.V. Monoamine oxidase
inhibitory activity: Methyl- versus Chloro chalcone derivatives. Chem. Med. Chem. 2016, 11, 2649–2655. [CrossRef]
31. Mathew, B.; Mathew, G.E.; Ucar, G.; Joy, M.; Nafna, E.K.; Lohidakshan, K.K.; Suresh, J. Monoamine oxidase inhibitory activity of
methoxy-substituted chalcones. Int. J. Biol. Macromol. 2017, 104, 1321–1329. [CrossRef] [PubMed]
32. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Chalcones: A
valid scaffold for monoamine oxidases inhibitors. J. Med. Chem. 2009, 52, 2818–2824. [CrossRef]
33. Minders, C.; Petzer, J.P.; Petzer, A.; Lourens, A.C. Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorg. Med.
Chem. Lett. 2015, 25, 5270–5276. [CrossRef]
34. Sasidharan, R.; Manju, S.L.; Uçar, G.; Baysal, I.; Mathew, B. Identification of indole-based chalcones: Discovery of a potent,
selective, and reversible class of MAO-B inhibitors. Arch. Pharm. 2016, 349, 627–637. [CrossRef]
35. Mathew, B.; Haridas, A.; Uçar, G.; Baysal, I.; Joy, M.; Mathew, G.E.; Lakshmanan, B.; Jayaprakash, V. Synthesis, biochemistry, and
computational studies of brominated thienyl chalcones: A new class of reversible MAO-B Inhibitors. Chem. Med. Chem. 2016, 11,
36. Xiao, G.; Li, Y.; Qiang, X.; Xu, R.; Zheng, Y.; Cao, Z.; Luo, L.; Yang, X.; Sang, Z.; Su, F.; et al. Design, synthesis and biological
0
evaluation of 4 -aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg.
Med. Chem. 2017, 25, 1030–1041. [CrossRef]
37. Cao, Z.; Yang, J.; Xu, R.; Song, Q.; Zhang, X.; Liu, H.; Qiang, X.; Li, Y.; Tan, Z.; Deng, Y. Design, synthesis and evaluation of
0
4 -OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment. Bioorg. Med. Chem.
38. Sasidharan, R.; Baek, S.C.; Sreedharannair Leelabaiamma, M.; Kim, H.; Mathew, B. Imidazole bearing chalcones as a new class of
monoamine oxidase inhibitors. Biomed. Pharmacother. 2018, 106, 8–13. [CrossRef] [PubMed]
39. Suresh, J.; Baek, S.C.; Ramakrishnan, S.P.; Kim, H.; Mathew, B. Discovery of potent and reversible MAO-B inhibitors as
furanochalcones. Int. J. Biol. Macromol. 2018, 108, 660–664. [CrossRef]
40. Reeta; Baek, S.C.; Lee, J.P.; Rangarajan, T.M.; Ayushee; Singh, R.P.; Singh, M.; Mangiatordi, G.F.; Nicolotti, O.; Kim, H.; et al. Ethyl
acetohydroxamate incorporated chalcones: Unveiling a novel class of chalcones for multitarget monoamine oxidase-B inhibitors
against Alzheimer’s disease. CNS Neurol. Disord. Drug Targets 2019, 18, 643–654. [CrossRef]
41. Mathew, B.; Baek, S.C.; Thomas Parambi, D.G.; Lee, J.P.; Mathew, G.E.; Jayanthi, S.; Vinod, D.; Rapheal, C.; Devikrishna, V.;
Kondarath, S.S.; et al. Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of
morpholine versus imidazole. Arch. Pharm. 2019, 352, e1800309. [CrossRef] [PubMed]
42. Parambi, D.G.T.; Oh, J.M.; Baek, S.C.; Lee, J.P.; Tondo, A.R.; Nicolotti, O.; Kim, H.; Mathew, B. Design, synthesis and biological
evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors. Bioorg. Chem. 2019, 93, 103335. [CrossRef]
43. Sang, Z.; Wang, K.; Zhang, P.; Shi, J.; Liu, W.; Tan, Z. Design, synthesis, in-silico and biological evaluation of novel chalcone
derivatives as multi-function agents for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2019, 180, 238–252. [CrossRef]
44. Zhang, X.; Song, Q.; Cao, Z.; Li, Y.; Tian, C.; Yang, Z.; Zhang, H.; Deng, Y. Design, synthesis and evaluation of chalcone Mannich
base derivatives as multifunctional agents for the potential treatment of Alzheimer’s disease. Bioorg. Chem. 2019, 87, 395–408.
45. Shalaby, R.; Petzer, J.P.; Petzer, A.; Ashraf, U.M.; Atari, E.; Alasmari, F.; Kumarasamy, S.; Sari, Y.; Khalil, A. SAR and molecular
mechanism studies of monoamine oxidase inhibition by selected chalcone analogs. J. Enzyme Inhib. Med. Chem. 2019, 34, 863–876.
46. Bai, P.; Wang, K.; Zhang, P.; Shi, J.; Cheng, X.; Zhang, Q.; Zheng, C.; Cheng, Y.; Yang, J.; Lu, X.; et al. Development of chalcone-O-
alkylamine derivatives as multifunctional agents against Alzheimer’s disease. Eur. J. Med. Chem. 2019, 183, 111737. [CrossRef]
47. Oh, J.M.; Rangarajan, T.M.; Chaudhary, R.; Singh, R.P.; Singh, M.; Singh, R.P.; Tondo, A.R.; Gambacorta, N.; Nicolotti, O.; Mathew,
B.; et al. Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors. Molecules 2020
,
48. Jeong, G.S.; Kaipakasseri, S.; Lee, S.R.; Marraiki, N.; Batiha, G.E.; Dev, S.; Palakkathondi, A.; Kavully, F.S.; Gambacorta, N.;
Nicolotti, O.; et al. Selected 1,3-benzodioxine-containing chalcones as multipotent oxidase and acetylcholinesterase inhibitors.
49. Kong, Z.; Sun, D.; Jiang, Y.; Hu, Y. Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and
reversible inhibitors of human monoamine oxidase B. J. Enzyme Inhib. Med. Chem. 2020, 35, 1513–1523. [CrossRef] [PubMed]